Key points
- First-in-human ventricular ablation guided by real-time iCMR successfully performed at Amsterdam University Medical Centre
- Procedure marks the initiation of the VISABL-VT clinical trial
- Procedure was the first ventricular ablation and first left-sided ablation to be performed under real-time MRI guidance
Full summary
Imricor Medical Systems, Inc. (ASX: IMR) has announced that it has commenced the VISABL-VT clinical trial after completing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) with the Company's NorthStar Mapping System. The procedure was successfully performed by the team at Amsterdam University Medical Centre (AUMC), ranked in 2025 by Newsweek as the best hospital in The Netherlands, and in the top 35 worldwide. The procedure marked several world firsts. It was the first ventricular ablation to be guided real-time MRI, and it was the first left-sided ablation to be performed under real-time MRI guidance. The patient was treated for right-sided and left-sided premature ventricular complexes (PVCs). Imricor's Chair and CEO, Steve Wedan, commented that this milestone represents the start of a new era for Imricor and electrophysiology, as the company strives to make interventional medical procedures better, safer, and more cost effective by enabling them to be performed under real-time MRI guidance.
Outlook
Imricor intends to seek approval for expanded indications for its Vision-MR Ablation Catheter in the future. The company is also pursuing the required regulatory approvals to place its key products on the market in the U.S. and other Middle East countries.